One of longevity's most intriguing ideas, and one of its least understood: a peptide only a few amino acids long, drawn from one organ, proposed to signal that same organ to work as it did in youth. Researched since Soviet times, and explained here by people who have actually read the primary science.
FIG.01 · EPITALON · STRUCTURE
Each is a chain of just two to four amino acids, short enough in principle to slip inside a cell and influence which genes it reads. A simple idea, aimed at something ambitious. The cell-culture support is real; how much reaches a living human is what we hold to the evidence, page by page.
In cell culture, some of these peptides settle onto specific stretches of DNA and shift which proteins a cell makes. Whether that repairs anything in a living person is unknown.
Ageing cell lines show shifted gene activity. Calling that "younger cells" in a human goes well past the data.
Each peptide comes from one organ and is meant to target it. That is the theory; the human evidence an oral dose gets there barely exists.
The research began in the 1970s in the Soviet military-medical system and continued in Russia for four decades. You will often see this history recast as a "secret Soviet super-peptide" reserved for cosmonauts and elite soldiers. That framing is marketing, not evidence: where a compound came from tells you nothing about whether it works.
Led by Professor Vladimir Khavinson, the group pulled these ultra-short peptides from animal organs and tracked their effects on genes and tissue. Four decades of mostly Russian-language work followed. Much of it is preclinical or small-cohort, not the big controlled human trials the marketing implies, and we say so on every peptide page.